Management of Weight Gain Associated with Antipsychotics

References

• Aronne U: Epidemiology, morbidity, and treatment of over-weight and obesity. J Clin Psychiatry 2001; 62(Suppl 23):13–22
   Google Scholar
• Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP: The continuing epidemics of obesity and diabetes in the United States. JAMA 2001; 286:1195–1200
   PubMed Web of Science ®Google Scholar
• World Health Organization: Obesity Epidemic Puts Millions At Risk (press release). Retrieved February 2002, from http://www.who.int/archives/inf-pr-1997/en/pr 97–46.html
   Google Scholar
• Hochberg MC, Lethbridge-Cejku M, Scott WW, Jr, Reichle R, Plato CC, Tobin JB: The association of body weight, body fatness and body fat distribution with osteoarthritis of the knee: Data from the Baltimore Longitudinal Study of Aging. Rheumatol 1995; 22(3):488–493
   Google Scholar
• Millman RP, Carlisle CC, McGarvey ST, Eveloff SE, Levinson PD: Body fat distribution and sleep apnea severity in women. Chest 1995; 107(2):362–366
   PubMed Web of Science ®Google Scholar
• Huang Z, Willet WCD, Mason JE: Body weight, weight change, and risk for hypertension in women. Ann Intern Med 1998; 28:81–88
   Google Scholar
• Stamler R, Stamler J. Riedlinger WF, Algera G, Roberts RH: Weight and blood pressure. Findings in hypertension screening of 1 million Americans. JAMA 1978; 240(15):1607–1610
   Google Scholar
• Colditz GA, Willett WC, Rotnitzky A: Weight gain as a risk factor for clinical diabetes. Ann Intern Med 1995; 122:481–486
   PubMed Web of Science ®Google Scholar
• Willett WC, Manson JE, Rotnitzky A: Weight, weight change and coronary heart disease in women: Risk within the "nor-mal" weight range. JAMA 1995; 273:461–465
   PubMed Web of Science ®Google Scholar
• Must A, Spadano J. Coakley EH, Field AE, Colditz G, Dietz WH: The disease burden associated with overweight and obesity. JAMA 1999; 282(16):1523–1529
   PubMed Web of Science ®Google Scholar
• Rexrode KM, Hennekens CH, Willett WC: A prospective study of body mass index, weight change, and risk of stroke in women. JAMA 1997; 277:1539–1545
   PubMed Web of Science ®Google Scholar
• Practical Guide to the Identification, Evaluation,, and Treat-ment of overweight and Obesity in Adults. Retrieved February 2002, from http://www.nhIbi.nih.goviguidelines/obesity
   Google Scholar
• Allison DB, Fontaine KR, Moonseong H, IvIentore JL, Cappelleri JC, Chandler LP, Weiden PJ, Cheskin U: The distri-bution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999; 60:215–220
   PubMed Web of Science ®Google Scholar
• Allison DB, Casey DE. Antipsychotic-induced weight gain: A review of the literature, J Clin Psychiatry 2001; 62(Suppl 7):22–31
   PubMed Web of Science ®Google Scholar
• Allison DB. Mentore JL. Heo M. Chandler LP. Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic-induced weight gain: A comprehensive research synthesis. Am .1 Psychiatry 1999; 156(10:1686–1696
   Google Scholar
• Harmatz MG, Lapuc P: Behavior modification of overeating in a psychiatric population. J Consult Clin Pharmacol 1968: 32(5):583–587
   PubMedGoogle Scholar
• Rotatori AF, Fox R. Wicks A: Weight loss with psychiatric residents in a behavioral self-control program. Psychol Rep 1980; 46:483–486
   PubMed Web of Science ®Google Scholar
• Greenberg I, Chan S, Blackburn G: Non-pharmacologic and pharmacologic management of weight gain. J Clin Psychiatry 1999; 60(Suppl 21): 31–36.
   Google Scholar
• Centers for Disease Control, and Prevention, National Center for Chronic Disease Prevention and Health Promotion: Surgeon General–s Report on Physical Activity and Health. Atlanta, GA: CDC; 1996.
   Google Scholar
• McGuire MT, Wing RR, Klem ML, Seagle HM, Hill JO: Longterm maintenance of weight loss: Do people who lose weight through various weight loss methods use different behaviors to maintain their weight? Int J Obes Relat Metab Disord 1998; 22572–577
   Google Scholar
• Poston WSC, Foreyt JP: Successful management of the obese patient. Am Fam Physician 2000; 61:3615–3622
   PubMed Web of Science ®Google Scholar
• Davis BR, Blaufox MD, Oberman A, Wassertheil-Smoller S, Zimbaldi N, Cutler JA, Kirchner, Langford HG: Reduc-tion in long-term antihypertensive medication requirements. Effects of weight reduction by dietary intervention in overweight persons with mild hypertension. Arch Intern Med 1993; 153( 15):1773–1782
   Google Scholar
• Granberry MC, Fonseca VA: Insulin resistance syndrome: Options for treatment. South Med J 1999; 92:2–15
   PubMed Web of Science ®Google Scholar
• Rossner S, Sjostrom L, Noack R, Meinders AE, Naseda G: Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res 2000; 8(1):49–61
   PubMedGoogle Scholar
• Berke EM, Morden NE: Medical management of obesity. Am Fam Physician 2000; 62(2):419426
   Google Scholar
• Dickerson LM, Carek PJ: Drug therapy for obesity. Am Fam Physician 2000; 61(7):213 1-2138
   Google Scholar
• Yanovski SZ, Yanovski JA: Obesity. N Engl J Med 2002; 346(8):59 1-602
   Google Scholar
• Guy-Grand B, Apfelbaum M, Crepaldi G, Breis A, LeFebyre P, Turner P: International trial of long-term dexfenfluramine in obesity. Lancet 1989; 2(8672):1142–1145
   PubMed Web of Science ®Google Scholar
• Weintraub M, Sundaresan PR. Schuster B: Long-term weight control study. IV (weeks I56 to 190). The second double-blind phase. Clin Pharmacol Ther 1992; 51(5):608–614
   Google Scholar
• US Department of Health and Human Services interim pub-lic health recommendations: Cardiac vaivulopathy associated with exposure to fenfluramine or dex-fenfluramine. MMWR Morb Mortal Wkly Rep 19Y7; 46:1061
   Google Scholar
• Baptista T: Body weight gain induced by antipsychotic drugs: Mechanisms and management. Acta Psychiatr Scand 1999; 100:3–16.
   PubMed Web of Science ®Google Scholar
• Knox JM: A study of weight reducing diets in psychiatric in-patients. Br J Psychiatry 1980; 136:287–289
   PubMed Web of Science ®Google Scholar
• Klein B. Steel RI, Simon WE, Primavera LH: Reinforcement and weight loss in schizophrenics. Psycho1 Rep 1972: 30(12):581–582
   Google Scholar
• Sletten IW, Ognjanov V. Menendez S. Sundland D, El-Toumi A: Weight reduction with chlorphenetermine and phenmetrazine in obese psychiatric patients during chlorpromazine therapy. Curr Ther Rrs Clin Exp 1967; 9:570–575
   Google Scholar
• Vreeland B, Roemhelf-Hamm B, Menza M, Stern R, Touger-Decker R, Minsky S. Radler DR: Managing atypical antipsychotic-associated weight gain: The Healthy Living Program. Poster presented at 155th American Psychiatric Association Annual Meeting, May 18–23.2002, Philadelphia. PA
   Google Scholar
• Ball MP, Coons VB, Buchanon RW: A program for treat-ing olanzapine-related weight gain. Psychiatr Serv 2001; 52(7):967–969
   PubMed Web of Science ®Google Scholar
• Centorrino F, Wurtzman JJ, Duca KK. Kelleher JP, Fellman VH, Berry JM, Guay DM, Romeling M, Tardivo J, Kidwell JE, Fogarty KV: Comprehensive weight loss program for overweight subjects treated with atypical antipsychotics. Poster presented at 155th American Psychiatric Association Annual Meeting, May 18–23.2002. Philadelphia, PA
   Google Scholar
• O'Keefe C, Noordsy D, Liss T, Weiss H: Reversal of weight gain associated with antipsychotic treatment. Poster presented at 154th Annual American Psychiatric Association, May 2001, New Orleans, LA.
   Google Scholar
• Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, Mintz J, Marder SM: Novel antipsy-chotics: Comparison of weight gain liabilities. J Clin Psychiatry 1999; 60(6):358–363
   PubMed Web of Science ®Google Scholar
• Littrell KI-1, Petty RG, Hilligoss NM, Peabody CD, Johnson CG: Educational interventions for the management of antipsychotic-related weight gain. Poster presented at the New Clinical Drug Evaluation Unit (NCDEU) Meeting, May 2001, Phoenix, AZ.
   Google Scholar
• Goodall E, Oxtoby C, Richard R, Watkinson G, Brown D, Silverstone T: A clinical trial of the efficacy and acceptabil-ity of d-fenfluramine in the treatment of neuroleptic-induced obesity. Br J Psychiatry 1988; 153:208–213
   PubMed Web of Science ®Google Scholar
• Svacina S, Sonka J, Marek J: Dexfenfluramine in psychotic patients. Int J Eat Disord 1998; 24:335–338
   Google Scholar
• Kolakowska T, Gadhvi H, Molynetuc S: An open clinical trial of fenfluramine in chronic schizophrenia: A pilot study. Jot Clin Psychopharmacol 1987; 2:83–88
   Google Scholar
• Borovicka MC, Fuller MA, Konicki E, White JC, Steele VM, Jaskiw GE: Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. J Clin Psychiatry 2002; 63(4):345–348
   PubMed Web of Science ®Google Scholar
• Shannon PJ, Leonard D, Kidson MA: Fenfluramine and psy-chosis [letter]. J Clin Psychopharmacol 1996; 16:470–471
   Google Scholar
• Bagri S, Reddy O: Delirium with manic symptoms induced by diet pills [letter]. J Clin Psychiatry 1998; 59:83.
   Google Scholar
• Preval H, Pakyurek AM: Psychotic episode associated with dexfenfluramine. Am J Psychiatry 1997; 154(11):1624–1625
   PubMed Web of Science ®Google Scholar
• Tafunski T, Chojnacka J: Sibutramine-associated psychotic episode. Am I Psychiatry 2000; 157:2056–2057
   Google Scholar
• Stromberg U, Svensson TH, Waldeck B: On the mode of action of amantadine. J Pharm Pharmacol 1970; 22(12):959–962
   Google Scholar
• Konig P. Chwatal K, Havelec L, Riedl F, Schubert H, Schultes H: Amantadine versus biperiden: A double-blind study of treatment efficacy in neuroleptic extrapyramidal movement disorders. Neuropsychobiology 1996; 33(12):80–84
   Google Scholar
• Floris M, Lejeune 1, Deberdt W: Effect of amantadine on weight gain during olanzapine treatment [case report]. Eur Neuropsychopharmacol 2001; 11(2):181–182
   Google Scholar
• Baruch R. Poulin M, Thakur A, Karagianis J, Raskin J: Amantadine induces weight loss in patients treated with olan-zapine. Schizophr Res 2002; 53(3 Suppl 1):159
   Google Scholar
• Wilcox and Tsuang: Psychological effects of amantadine on psychotic subjects. Neuropsychobiology 1990; 23(3):144–146
   Google Scholar
• Stoa-Birketvedt G: Effect of cimetidine suspension on ap-petite and weight in overweight subjects. BMJ 1993; 30:1091–1093
   Google Scholar
• Stoa-Birketvedt G, Paus PN, Ganss R, Ingebretsen OC, Florholmen J: Cimetidine reduces weight and improves metabolic control in overweight patients with type 2 diabetes. lot J Obes Relat Metab Disord 1998; 22(11):1041–1045
   Google Scholar
• Sacchetti E, Guarneri L, Bravi D: H2 antagonist niza-ticline may control olanzapine-associated weight gain in schizophrenic patients. Biol Psychiatry 2000; 48(2):167–168
   PubMed Web of Science ®Google Scholar
• Breier A. Tanaka Y, Roychowdhury S. Clark WS: Nizatidine for the prevention of olanzapine-associated weight gain in schizophrenia and related disorders-a randomized controlled double-blind study. Poster presented at the 41st New Clini-cal Drug Evaluation Unit, Lilly Research Laboratories, May 28–31,2001, Phoenix, AZ. Unpublished data
   Google Scholar
• Bailey CJ, Turner RC: Metformin. N Engl J Med 1996; 334:574–579
   PubMed Web of Science ®Google Scholar
• Fontbonne A. Charles MA, Juhan-Vague I, Bard JM, Andre P. Isnard F, Cohen JM, Grandmottet P. Vague P. Safar ME, Eschwege E: The effect of metformin on the metabolic abnor-malities associated with upper-body fat distribution. Results of the BIGPRO 1 trial. Diabetes Care 1996; 19(9):920–926
   Google Scholar
• Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med 2002; 346(6):393–403
   PubMed Web of Science ®Google Scholar
• Morrison J, Cottingham EM, Barton BA: Metfonnin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry 2002; 159(4):655–657
   PubMed Web of Science ®Google Scholar
• Glucophage Prescribing Information. Bristol Myers Squibb Company, New York, NY, June 2001
   Google Scholar
• Al-Jebawi AF, Lassman MN, Abourizk NN: Lactic acidosis with therapeutic metformin blood level in a low-risk diabetic patient. Diabetes Care 1998; 21(8):1364–1365
   Google Scholar
• Marcotte D: Use of topiramate, a new anti-epileptic as a mood stabilizer. J Affect Disord 1998; 50:245–251
   PubMed Web of Science ®Google Scholar
• Gordon A, Price LH: Mood stabilization and weight loss with topiramate. Am J Psychiatry 1999; 156:968–969
   PubMed Web of Science ®Google Scholar
• Norton J, Potter D, Edwards K: Sustained weight loss associ-ated with topiramate. Epilepsia 1997; 38(Suppl 3):58
   Google Scholar
• Dursun SM, Devarajan S: Clozapine weight gain, plus topira-mate weight loss. Can J Psychiatry 2000; 45:198.
   PubMed Web of Science ®Google Scholar
• Chengappa KN, Levine J, Rathore D, Parepally H, Atzert R: Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: A case-series. Eur Psy-chiatry 2001; 16:186–190
   Google Scholar
• Littrell KH, Petty RG, Hilligoss NM, Peabody CD, Johnson CG: Weight loss with topiramate. Ann Pharrnacother 2001; 35:1141–1142
   Google Scholar
• Meyer JM: Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry 2001; 62(Suppl 27):27–34
   PubMed Web of Science ®Google Scholar
• Dinan TG, Tobin A: Orlistat in the management of antipsychotic-induced weight gain: Two case reports. J Sero-tonin Res 2001; 7:14–15
   Google Scholar
• Anghelescu I, Klawe C, Benkert O: Orlistat in the treatment of psychopharmacologically induced weight gain. .1 Clin Psy-chopharmacol 2000; 20(6):716–717
   Google Scholar
• Nagele H. Peterson B, Bonacker U, Rudiger W: Effect of orlistat on blood cyclosporine concentrations in an obese heart transplant patient. Eur J Clin Pharmacol 1999; 55:667–669
   PubMed Web of Science ®Google Scholar
• Hilger E, Quiner S, Ginzel I, Walter H, Saria L, Barnas C: The effect of orlistat on plasma levels of psychotropic drugs in patients with long-term psychopharrnacotherapy. J Clin Psy-chopharmacol 2002; 22:68–70
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kivkaanniemi S, Laakso M, Louheranta A, Raslas M, Salminen V, Uusitupa M: Prevention of type 2 diabetes mellitus by changes in lifestyle among sub-jects with impaired glucose tolerance. N Engl .1 Med 2001; 344(18):1343–1350
   Google Scholar